Item
「アビガン」近く承認申請へ 国産“第1号”に期待(2020年9月21日)
Title (Dublin Core)
「アビガン」近く承認申請へ 国産“第1号”に期待(2020年9月21日)
Approval application for "Abigan" Expectations for the first Japanese drug (September 21, 2020)
Translated by Youngbin Noh 09/28/2020
Translated by Youngbin Noh 09/28/2020
Description (Dublin Core)
It is a video from ANN news in Japan, where Avigan made by Fujifilm Toyama Chemical Co., Ltd. is in the process of applying for marketing aproval of this drug. Avigan is thought to help COVID-19 and its symptoms. FUJIFILM Toyama Chemical has been conducting clinical trials for Avigan since the end of March 2020, and by the middle of this month, they will have all the data needed According to the news, the data is being analyzed, the efficacy and safety being reviews, and the application for manufacturing and marketing approval will be submitted soon. After the application, the Ministry of Health, Labor and Welfare will examine the safety and decide whether to approve it. If the application for Fujifilm is approved, it will be the first new corona treatment developed in Japan. FUJIFILM says, "I want to proceed with data analysis as soon as possible."
Date (Dublin Core)
Creator (Dublin Core)
Event Identifier (Dublin Core)
Partner (Dublin Core)
Type (Dublin Core)
Screenshot
Link (Bibliographic Ontology)
https://www.youtube.com/watch?v=Vrtc7NPwhak
Publisher (Dublin Core)
ANN
Controlled Vocabulary (Dublin Core)
Curator's Tags (Omeka Classic)
Linked Data (Dublin Core)
Date Submitted (Dublin Core)
09/21/2020
Date Modified (Dublin Core)
09/28/2020
09/29/2020
Date Created (Dublin Core)
09/21/2020
Format (Dublin Core)
Video
Language (Dublin Core)
Japanese
Transcription (Omeka Classic)
新型コロナウイルスの治療薬として期待される「アビガン」について、開発を進めている富士フイルム富山化学が近く国に製造販売の承認を申請することが分かりました。
富士フイルム富山化学はアビガンについて3月末から臨床試験を実施していて、今月中旬までに必要な患者のデータなどがそろったということです。現在、データの解析が進められていて、有効性や安全性を最終確認し、近く国に製造販売の承認を申請します。申請後は厚生労働省が安全性などを審査し、承認するかどうか判断します。富士フイルムの申請が承認されれば、日本で開発された新型コロナ治療薬の第1号となります。富士フイルムは「できるだけ速やかにデータの解析を進めたい」としています。
[テレ朝ｎｅｗｓ] https://news.tv-asahi.co.jp
富士フイルム富山化学はアビガンについて3月末から臨床試験を実施していて、今月中旬までに必要な患者のデータなどがそろったということです。現在、データの解析が進められていて、有効性や安全性を最終確認し、近く国に製造販売の承認を申請します。申請後は厚生労働省が安全性などを審査し、承認するかどうか判断します。富士フイルムの申請が承認されれば、日本で開発された新型コロナ治療薬の第1号となります。富士フイルムは「できるだけ速やかにデータの解析を進めたい」としています。
[テレ朝ｎｅｗｓ] https://news.tv-asahi.co.jp
Fujifilm Toyama Chemical Co., Ltd., which is developing "Abigan", which is expected to be a therapeutic drug for the new coronavirus, will soon apply for manufacturing and marketing approval to the country.
FUJIFILM Toyama Chemical has been conducting clinical trials for Abigan since the end of March, and by the middle of this month, they have all the necessary patient data. Currently, the data is being analyzed, the efficacy and safety will be finalized, and an application for manufacturing and marketing approval will be submitted to the country soon. After the application, the Ministry of Health, Labor, and Welfare will examine the safety and decide whether to approve it. If the application for Fujifilm is approved, it will be the first new corona treatment developed in Japan. FUJIFILM says, "I want to proceed with data analysis as soon as possible."
[TV Asahi news] https://news.tv-asahi.co.jp
Translated by Youngbin Noh 09/28/202
FUJIFILM Toyama Chemical has been conducting clinical trials for Abigan since the end of March, and by the middle of this month, they have all the necessary patient data. Currently, the data is being analyzed, the efficacy and safety will be finalized, and an application for manufacturing and marketing approval will be submitted to the country soon. After the application, the Ministry of Health, Labor, and Welfare will examine the safety and decide whether to approve it. If the application for Fujifilm is approved, it will be the first new corona treatment developed in Japan. FUJIFILM says, "I want to proceed with data analysis as soon as possible."
[TV Asahi news] https://news.tv-asahi.co.jp
Translated by Youngbin Noh 09/28/202
Original Format (Omeka Classic)
Youtube
Compression (Omeka Classic)
1:01 minutes
This item was submitted on September 21, 2020 by [anonymous user] using the form “Share Your Story” on the site “A Journal of the Plague Year”: http://mail.covid-19archive.org/s/archive
Click here to view the collected data.